Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06830798 · ClinicalTrials.gov registry record · Phase 3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
A Phase 3 study of Kidney Transplant and Delayed Graft Function, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06830798: Recruiting Phase 3 study of Kidney Transplant and Delayed Graft Function, sponsored by Alexion Pharmaceuticals.
NCT06830798 is a Phase 3 study of Kidney Transplant and Delayed Graft Function that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 450 participants, below the 1,883-participant average among 30 other Kidney Transplant trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06830798, a Phase 3 study of Kidney Transplant and Delayed Graft Function, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ravulizumab
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - San Francisco
- Research Site - San Francisco
- Research Site - Stanford
Florida
- Research Site - Jacksonville
- Research Site - Tampa
Illinois
- Research Site - Chicago
- Research Site - Chicago
Michigan
- Research Site - Ann Arbor
- Research Site - Detroit
Arizona
- Research Site - Phoenix
Connecticut
- Research Site - New Haven
Georgia
- Research Site - Atlanta
Kansas
- Research Site - Fairway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-05-19 |
| Est. Completion | 2028-11-06 |
| Phase | Phase 3 |
What NCT06830798 shows while recruiting
NCT06830798 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 1,883-participant average among 30 other Kidney Transplant trials with a reported enrollment target (76% lower).
The record links to 3 conditions, with Kidney Transplant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06830798 names 20 study sites across 14 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT06830798 about?
NCT06830798 is a clinical study titled "Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation". The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.
What is the current status of trial NCT06830798?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2025-05-19. Estimated completion is 2028-11-06.
What conditions does trial NCT06830798 study?
This clinical trial studies the following conditions: Kidney Transplant, Delayed Graft Function, DGF.
What interventions are being tested in trial NCT06830798?
The interventions under investigation include: Placebo (DRUG), Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT06830798?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06830798 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06830798's enrollment target sits among peer trials
450 4th of 30 higher than 27 of 30 other Kidney Transplant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
RECRUITING · Phase 3
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
Social Support Counseling Intervention for Kidney Transplant Candidates
RECRUITING · NA
-
Advancing Transplantation Outcomes in Children
RECRUITING · Phase 2
-
Adipose-derived MSC to Treat Rejection in Kidney Transplant Recipients
RECRUITING · Phase 1
-
Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI